Simplexa™ COVID-19/ Flu A/B & RSV Direct (MOL4450); Simplexa™ COVID-19/ Flu A/B & RSV Positive Control Pack (MOL4460)— 510(k) K252387

Substantially Equivalent

Diasorin Molecular, LLC

FDA 510(k) clearance K252387 for Simplexa™ COVID-19/ Flu A/B & RSV Direct (MOL4450); Simplexa™ COVID-19/ Flu A/B & RSV Positive Control Pack (MOL4460), Substantially Equivalent on 2025-10-30. Applicant: Diasorin Molecular, LLC.

Clearance details

Applicant
Diasorin Molecular, LLC
Product code
Code QOF
Advisory panel
Microbiology
Date received
Decision date
Decision
Substantially Equivalent
Clearance type
Traditional
Location
Cypress, CA, US
Download summary PDFView on FDA.gov ↗

Data sourced from openFDA. This site is unofficial and independent of the FDA.